MaaT Pharma

MaaT Pharma eyes Phase II after early success in ALS microbiome trial
Clinical Trials Arena
Tue, 11/26/24 - 11:23 am
MaaT Pharma
ALS
clinical trials
microbiome
MaaT-033
MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement
Clinical Trials Arena
Mon, 04/15/24 - 11:20 am
MaaT Pharma
MaaT013
graft vs host disease
clinical trials
Microbiome-based treatment shows potential in graft-versus-host disease
Biopharma Reporter
Tue, 12/19/23 - 10:16 am
MaaT Pharma
microbiome
graft vs host disease
MaaT013
After 20-month hold, FDA drops resistance to fecal pooling, clears MaaT to run pivotal trial
Fierce Biotech
Tue, 04/25/23 - 10:37 am
MaaT Pharma
FDA
clinical trials
fecal therapy
graft vs host disease
Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with FDA
Fierce Biotech
Fri, 02/3/23 - 10:55 am
MaaT Pharma
microbiome
FDA
fecal microbiome
MaaT013
FDA declines to free MaaT's microbiome drug from clinical hold after a year
Fierce Biotech
Wed, 08/10/22 - 11:31 pm
MaaT Pharma
FDA
microbiome
clinical trials
graft vs host disease
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year
Fierce Biotech
Mon, 01/24/22 - 10:14 am
MaaT Pharma
microbiome
clinical trials
AML
MaaT bags €18M to test microbiome modulators in cancer patients
Fierce Biotech
Wed, 02/5/20 - 10:15 am
MaaT Pharma
solid tumors
graft vs host disease
Microbiome Report for Week Ending 5/11/19
CP Wire
Fri, 05/17/19 - 09:56 am
icrobiome
Vedanta Biosciences
MaaT Pharma
Acute GvHD
patents
Microbiome Report for Week Ending 5/11/19
Fri, 05/17/19 - 09:55 am
microbiome
Vedanta Biosciences
MaaT Pharma
Acute GvHD
patents
Microbiome Report for Week Ending 4/13/19
CP Wire
Thu, 04/18/19 - 10:33 pm
MaaT Pharma
MaaT013
aGvHD
Second Genome
SkinBio Therapeutics
Azitram AZT-02
Netherton Syndrome
Microbiome Report for Week Ending 4/13/19
Thu, 04/18/19 - 10:31 pm
MaaT Pharma
MaaT013
aGvHD
Second Genome
SkinBio Therapeutics
Azitram AZT-02
Netherton Syndrome
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Ph II Study in Acute GvHD
CP Wire
Wed, 04/10/19 - 11:31 pm
MaaT Pharma
graft vs host disease
MaaT013
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Ph II Study in Acute GvHD
Wed, 04/10/19 - 09:24 pm
MaaT Pharma
graft vs host disease
MaaT013
MaaT Pharma Releases Results Of Microbiome Restoration Therapy in Acute Myeloid Leukemia Patients
CP Wire
Fri, 11/2/18 - 09:38 am
MaaT Pharma
acute myeloid leukemia
microbiome
MaaT Pharma Releases Results Of Microbiome Restoration Therapy in Acute Myeloid Leukemia Patients
Fri, 11/2/18 - 09:34 am
MaaT Pharma
acute myeloid leukemia
microbiome
MaaT Pharma Presents Analysis of Its First-in-Class High Diversity Microbiome Therapeutic
CP WIre
Wed, 09/19/18 - 11:15 pm
microbiome
MaaT Pharma
MaaT Pharma Presents Analysis of Its First-in-Class High Diversity Microbiome Therapeutic
Wed, 09/19/18 - 10:57 pm
MaaT Pharma